Challenges and Controversies in Resectable Non-small Cell Lung Cancer: a Clinician's Perspective

Overview

Journal Lancet Reg Health Eur

Specialty Health Services

Date 2024 Mar 13

PMID 38476749

Authors

Ilias Houda

Chris Dickhoff

Carin A Uyl-de Groot

Ronald A M Damhuis

Noemi Reguart

Mariano Provencio

Antonin Levy

Rafal Dziadziuszko

Cecilia Pompili

Massimo Di Maio

Michael Thomas

Alessandro Brunelli

Sanjay Popat

Suresh Senan

Idris Bahce

Affiliations

Soon will be listed here.

Abstract

The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is transforming due to the approval of novel adjuvant and neoadjuvant systemic treatments. The European Medicines Agency (EMA) recently approved adjuvant osimertinib, adjuvant atezolizumab, adjuvant pembrolizumab, and neoadjuvant nivolumab combined with chemotherapy, and the approval of other agents or new indications may follow soon. Despite encouraging results, many unaddressed questions remain. Moreover, the transformed treatment paradigm in resectable NSCLC can pose major challenges to healthcare systems and magnify existing disparities in care as differences in reimbursement may vary across different European countries. This Viewpoint discusses the challenges and controversies in resectable early-stage NSCLC and how existing inequalities in access to these treatments could be addressed.

Citing Articles

Real-World Analysis of Survival and Treatment Efficacy in Stage IIIA-N2 Non-Small Cell Lung Cancer.

Josephides E, Dunn R, Henry A, Pilling J, Harrison-Phipps K, Patel A Cancers (Basel). 2024; 16(17).

PMID: 39272916 PMC: 11394025. DOI: 10.3390/cancers16173058.

Nose-on-Chip Nanobiosensors for Early Detection of Lung Cancer Breath Biomarkers.

Chaudhary V, Taha B, Lucky , Rustagi S, Khosla A, Papakonstantinou P ACS Sens. 2024; 9(9):4469-4494.

PMID: 39248694 PMC: 11443536. DOI: 10.1021/acssensors.4c01524.

Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions.

Garg P, Singhal S, Kulkarni P, Horne D, Malhotra J, Salgia R J Clin Med. 2024; 13(14).

PMID: 39064229 PMC: 11278207. DOI: 10.3390/jcm13144189.

Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish lung cancer group GECP. Controversies and discussion.

Navarro Martin A, Rodriguez de Dios N, Lopez Guerra J, Counago Lorenzo F Clin Transl Oncol. 2024; 27(1):393-394.

PMID: 38967740 DOI: 10.1007/s12094-024-03540-2.

Disparity of the Treatment of Unresectable Non-small Cell Lung Cancer Regarding Chemotherapy: A Systematic Review and Meta-Analysis.

Ohta R, Sano C Cureus. 2024; 16(5):e60635.

PMID: 38899245 PMC: 11185987. DOI: 10.7759/cureus.60635.

References

Pataer A, Kalhor N, Correa A, Raso M, Erasmus J, Kim E . Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2012; 7(5):825-32. PMC: 3465940. DOI: 10.1097/JTO.0b013e318247504a. View

Provencio M, Nadal E, Gonzalez-Larriba J, Martinez-Marti A, Bernabe R, Bosch-Barrera J . Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2023; 389(6):504-513. DOI: 10.1056/NEJMoa2215530. View

Hofmarcher T, Szilagyiova P, Gustafsson A, Dolezal T, Rutkowski P, Baxter C . Access to novel cancer medicines in four countries in Central and Eastern Europe in relation to clinical benefit. ESMO Open. 2023; 8(4):101593. PMC: 10485399. DOI: 10.1016/j.esmoop.2023.101593. View

Senan S, Ozguroglu M, Daniel D, Villegas A, Vicente D, Murakami S . Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial. ESMO Open. 2022; 7(2):100410. PMC: 9058904. DOI: 10.1016/j.esmoop.2022.100410. View

Wait S, Alvarez-Rosete A, Osama T, Bancroft D, Cornelissen R, Marusic A . Implementing Lung Cancer Screening in Europe: Taking a Systems Approach. JTO Clin Res Rep. 2022; 3(5):100329. PMC: 9121320. DOI: 10.1016/j.jtocrr.2022.100329. View

Vrdoljak E, Bodoky G, Jassem J, Popescu R, Mardiak J, Pirker R . Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement. Oncologist. 2016; 21(10):1183-1190. PMC: 5061531. DOI: 10.1634/theoncologist.2016-0137. View

Houda I, Dickhoff C, Uyl-de Groot C, Reguart N, Provencio M, Levy A . New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe. Lancet Reg Health Eur. 2024; 38:100840. PMC: 10928304. DOI: 10.1016/j.lanepe.2024.100840. View

Walters S, Benitez-Majano S, Muller P, Coleman M, Allemani C, Butler J . Is England closing the international gap in cancer survival?. Br J Cancer. 2015; 113(5):848-60. PMC: 4559829. DOI: 10.1038/bjc.2015.265. View

Eberhardt W, Pottgen C, Gauler T, Friedel G, Veit S, Heinrich V . Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). J Clin Oncol. 2015; 33(35):4194-201. DOI: 10.1200/JCO.2015.62.6812. View

10.

Bayle A, Bonastre J, Chaltiel D, Latino N, Rouleau E, Peters S . ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe. Ann Oncol. 2023; 34(10):934-945. DOI: 10.1016/j.annonc.2023.06.011. View

11.

Hoeijmakers F, Heineman D, Daniels J, Beck N, Tollenaar R, Wouters M . Variation Between Multidisciplinary Tumor Boards in Clinical Staging and Treatment Recommendations for Patients With Locally Advanced Non-small Cell Lung Cancer. Chest. 2020; 158(6):2675-2687. PMC: 7768935. DOI: 10.1016/j.chest.2020.07.054. View

12.

Heymach J, Harpole D, Mitsudomi T, Taube J, Galffy G, Hochmair M . Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. N Engl J Med. 2023; 389(18):1672-1684. DOI: 10.1056/NEJMoa2304875. View

13.

Postmus P, Kerr K, Oudkerk M, Senan S, Waller D, Vansteenkiste J . Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4):iv1-iv21. DOI: 10.1093/annonc/mdx222. View

14.

OBrien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L . Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022; 23(10):1274-1286. DOI: 10.1016/S1470-2045(22)00518-6. View

15.

Felip E, Rosell R, Maestre J, Rodriguez-Paniagua J, Moran T, Astudillo J . Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol. 2010; 28(19):3138-45. DOI: 10.1200/JCO.2009.27.6204. View

16.

Felip E, Altorki N, Zhou C, Csoszi T, Vynnychenko I, Goloborodko O . Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021; 398(10308):1344-1357. DOI: 10.1016/S0140-6736(21)02098-5. View

17.

Franceschini D, Bruni A, Borghetti P, Giaj-Levra N, Ramella S, Buffoni L . Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetings. Radiol Med. 2019; 125(2):214-219. DOI: 10.1007/s11547-019-01094-w. View

18.

Konig D, Schar S, Vuong D, Guckenberger M, Furrer K, Opitz I . Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials. ESMO Open. 2022; 7(2):100455. PMC: 9011017. DOI: 10.1016/j.esmoop.2022.100455. View

19.

Provencio M, Calvo V, Romero A, Spicer J, Cruz-Bermudez A . Treatment Sequencing in Resectable Lung Cancer: The Good and the Bad of Adjuvant Versus Neoadjuvant Therapy. Am Soc Clin Oncol Educ Book. 2022; 42:1-18. DOI: 10.1200/EDBK_358995. View

20.

Passiglia F, Calandri M, Guerrera F, Malapelle U, Mangone L, Ramella S . Lung Cancer in Italy. J Thorac Oncol. 2019; 14(12):2046-2052. DOI: 10.1016/j.jtho.2019.05.019. View